Our blog

The General University Hospital of Catalonia, a reference in Alzheimer’s research

5 de November de 2019

Neurology and Neuropsychology team specializes in the evaluation of biomarkers and the early diagnosis of…

Compartir:
Posted in: Alzeimer

A new algorithm allows to identify the people with more Alzheimer’s risk

5 de November de 2019

The Pasqual Maragall Foundation develops a method based on magnetic resonance imaging It allows to…

Compartir:
Posted in: Alzeimer, Uncategorised

New clinical trials are looking for a cure to avoid 100 million of new patients in 2050.

25 de October de 2019

The General University Hospital of Catalonia analyzes in two proteins and in a gum bacterium…

Compartir:
Posted in: Alzeimer

We started an intravenous antiamyloid therapy in mild Alzheimer’s

20 de September de 2019

Our team participated in a phase II clinical trial, with an antiamyloid monoclonal antibody in…

Compartir:
Posted in: Alzeimer

Dental infection and Alzheimer’s disease

6 de September de 2019

We have initiated a clinical trial to assess the efficacy and safety of a drug…

Compartir:
Posted in: Alzeimer

Progressive Supranuclear Paralysis (PSP): An Innovative Therapy

19 de July de 2019

We have been selected to evaluate an innovative therapy in this terrible disease. We will…

Compartir:
Posted in: Uncategorised

Another terapeutic target in Alzheimer disease

9 de May de 2019

We started a phase II / III trial with an inhibitor of TAU protein aggregation…

Compartir:
Posted in: Alzeimer

Novel contribution to the treatment of motor fluctuations in Parkinson’s

27 de March de 2019

New formulation of combined action Levodopa We have started the evaluation of a new preparation…

Compartir:
Posted in: Parkinson

New antidiskinetic therapy in Parkinson’s disease

20 de March de 2019

We have started a clinical trial with a new antidiskinetic therapy (combination of two drugs…

Compartir:
Posted in: Parkinson

Advanced Parkinson’s disease treated with a levodopa pump

20 de March de 2019

The UDIC will shortly begin a clinical trial to evaluate the subcutaneous administration of levodopa,…

Compartir:
Posted in: Uncategorised

Anti-amyloid therapy in initial Alzheimer’s continues.

14 de March de 2019

Our Unit participated in a Phase II clinical trial, with a monoclonal anti-amyloid in Alzheimer’s,…

Compartir:
Posted in: Alzeimer, Uncategorised

The UDIC leads international recruitment in a phase II trial in Alzheimer’s disease.

1 de March de 2019

Our Unit has surpassed two centers from the United States in the randomization of patients included in a…

Compartir:
Posted in: Alzeimer, Uncategorised
Page 2 of 3 1 2 3

1 Nuevo anticuerpo monoclonal antialfasinucleina Ensayo Clínico de fase II para evaluar eficacia y seguridad
en enfermedad de Parkinson inicial en pacientes que no reciben medicamentos antiparkinsonianos en el momento actual. 2 Nuevo fármaco antipsicótico en cualquier tipo de demencia. Ensayo de Fase III que evalúa un antipsicótico
en cualquier tipo de delirio o alucinaciones. Sin acción antidopaminérgica, especialmente indicado en Parkinson
o en situaciones de mala respuesta a los neurolepticos
Compartir: